# Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint

> **Newsylist Open Intelligence Dossier** · First detected: 2026-09-22 21:29 UTC · Category: Business · Sources: 6 · Current Velocity: 3.67

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| firstwordpharma.com | Otsuka claims Phase III win for ulefnersen in rare genetic ALS | 2026-09-22 13:22 | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE5jNVpsU0Z1a0c0YnhUbURPWm1kRnhOWkI3MFlGSDFzNWlqQ1hKdW9MRHo4YmtlRnFjTFNOOWVVejRteEZuZlRRQXpLUVJxOWoydHhj?oc=5) |
| PR Newswire | ALS Association Statement on Positive Phase 3 Results for Ulefnersen in FUS-ALS | 2026-09-22 13:22 | [Source Link](https://news.google.com/rss/articles/CBMi0AFBVV95cUxON1JTVnBWNlVsSlY1eUZMNDFieUE5dVlDMnF3clVOZ3pPbXhYR3JDczRpSGhkdjRoOU1YS19pcm5KTlZDSHFoem1aaXdfZ1N6YXpzR3ZWVEFZWS1xMGd0NllVd1c0Nkh1dGtURWdaMmZwU0Vtalh4VHd0R2hvVjFpSldpMnFSN0sydllOeFlpczZKaXl3c2t1VzB5TkZiakJVTzd0QkRIVkE1RDZGOVVtQndoRHNfSE1ZN04zTVVqRUxBeFpjXzMwQkNJWTAya2JQ?oc=5) |
| Investing.com | Ionis drug meets primary goal in rare ALS gene mutation trial | 2026-09-22 13:22 | [Source Link](https://news.google.com/rss/articles/CBMiugFBVV95cUxNRjJha2xUSGpZMnN4dFN5dGh1MXVycnlXWHVkVHNsUUI5dG1yRTVGODVGUGhwYkpWRWJIcFVUY0Ytd01JbnpYeGtKekdkb0RzYUVoTmZxTmRoLUp6aFNmX0dtYUV1WUh0aVlGbTZrTVByaU5VeVBqazFnTG80OEQwTXYwcG5nTV9oRFBGQnlsb25XWVhDZzdWaU1jU1pQVE9rdTM3SGxPR3ZtbDlBenZqUnpEVHZQd2J4Smc?oc=5) |
| TradingView | Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile | 2026-09-22 13:22 | [Source Link](https://news.google.com/rss/articles/CBMi9AFBVV95cUxQSFl1Y0VBNW1NRUVNRGZoblh3QUlzaWZqSlMtVmVvTkVpeVExZkc1dEF0dzhjdFFPc3h4N0E4ekJNaVpWQWZEZTUxSWZlU3JzbURlT0xxRXYtZEh3SHdCTjkxREd1ZXE0S01rQXNRbGtqV1dJdkduNkNsRTY1R3pLYUs1dmNpVXJNdlViQ0hTUE9IaWszOWhVemtUMGJTMUNZYnl6WHp0NmxndktmWXRJbjFITy03U0xXQlVXNU5LT3p1S3dlSkhUVHhPYUIxRFpFZVZ6N3U0c0FEQXNCTndEMV9xTk9ycERWdG5jdi1Gd3oxTTUt?oc=5) |
| BioSpace | Otsuka Establishes Ulefnersen Early Access Program (EAP) for Eligible People Living with FUS-ALS | 2026-09-22 13:22 | [Source Link](https://news.google.com/rss/articles/CBMizwFBVV95cUxPSDVQZktlOEFGOWo1YUNYWFVJbWpMbTVCajhIVTkyQUhtVTRTcmNqZDVpVHR2N01BQWZ2VE9VNXJHZExhaGtGbjRMOXNfLTBiTWt0eEdfS0xEWUh2NVU4V1lIVVAxaHRyQjdkYWNDd21sMk9KMklQZDgzWlJGQ1VaSFZTM3ZuQjNROFFocDFFZE1yUWRxaUpVOWhfb3pFUHBNTWNBd292bjRlTlRnZDdVM3ZwYlM3N1M0NlJvMmY3SzNzN21obnlpTU5xNGs5RTQ?oc=5) |
| Fierce Biotech | Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint | 2026-09-22 13:22 | [Source Link](https://news.google.com/rss/articles/CBMirgFBVV95cUxQRXE5bXNhQzlYbkZaV0FxUkU3VkhiUnZiNDdnMERSUTdOX1AyejBLM3Y0WWw0STc3SGRGRzhQd3QxZ1BwN1UyWmh2NjBWUlRiZG9CenpNbjI5c3RYdmtad05aU3pBYTBBYWszSHE1OGNrM2YxTkpCU01fR3MwcktzakEtc3RldTZtTGhTYzEyTi1ybl9tN3VoTzR0bnNOM0taQ1VPLU9NdXl1NEh6dnc?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-09-22/otsuka-heads-to-fda-as-ionis-partnered-als-drug-hits-primary-phase-3-endpoint*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*